SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust ($SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new record highs in Shanghai and upcoming Chinese export restrictions. This surge is further fueled by critical industrial demand from AI data centers and green energy, prompting community discussion of a potential "silver squeeze" and a significant re-rating of silver's value, though some anticipate a near-term pullback after its rapid ascent.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending due to the FDA's recent approval of YARTEMLEA, its first-in-class treatment for transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening condition with no prior approved therapies. The community is actively discussing the stock's perceived undervaluation, potential for a short squeeze given high short interest, and the significant financial backing from its existing multi-billion dollar partnership with Novo Nordisk. Investors anticipate further clarity on drug pricing and commercial strategy, reinforcing conviction for a substantial long-term re-rating.

ProShares Trust - ProShares UltraShort Silver -2x Shares

ProShares UltraShort Silver

ProShares UltraShort Silver ($ZSL) is trending as traders aggressively position for a significant correction in silver, widely viewed as overextended after its recent strong rally. The community is actively debating the sustainability of silver's gains, with many utilizing this inverse ETF as a direct bearish bet or to hedge existing precious metal holdings against anticipated market shifts.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang (CPNG) is trending due to significant fallout from a major data breach, which has prompted a CEO resignation and ongoing government investigations, including police searches and potential large-scale lawsuits. Community sentiment reflects strong concern over the company's handling of the incident and its implications for consumer trust and business operations in South Korea, its primary market.

Bitwise 10 Crypto Index ETF - Common Shares Of Beneficial Interest

Bitwise 10 Crypto Index Fund

Bitwise 10 Crypto Index Fund is actively discussed amid a polarized crypto market, with strong bearish voices predicting a prolonged "crypto winter" while bullish investors point to increasing institutional adoption and positive fund inflows into the sector. A significant talking point for BITW is its notable trading discount to Net Asset Value, which the community anticipates could narrow as the fund progresses with its regulatory efforts to convert to an Exchange Traded Product. This potential structural change creates an arbitrage opportunity, driving conversation among those monitoring the fund's correlation to Bitcoin and other major digital assets.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending following its recent earnings report, which showcased revenue growth and an emphasized focus on providing essential on-site power for the surging AI-driven data center market. The community is actively discussing the potential for major contract conversions from their extensive pipeline of megawatts, with many viewing the company's natural gas-fueled solutions as a timely answer to the energy demands of hyperscalers, distinguishing it from other fuel cell players. This narrative, coupled with efforts to scale manufacturing and improve financials, fuels optimism for its path toward future profitability despite past challenges.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is trending amid news of its integration-ready post-quantum vault, enhancing its security. The community is actively discussing BCH's surprising resilience and outperformance compared to Bitcoin and other altcoins during a challenging market. Many believe it is significantly undervalued and poised for a major breakout, with speculation of large institutional interest driving this potential decoupling from broader market trends.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is generating significant buzz as investors anticipate its merger with quantum technology firm Infleqtion, fueled by recent bullish commentary from Citron Research. Community sentiment views Infleqtion as a highly undervalued leader in the quantum sector, differentiated by its real revenue, critical defense contracts for GPS-denied navigation, and advanced neutral-atom technology.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu is currently trending as its dedicated "Wolfpack" community actively promotes the recently launched WolfSwap, a cross-chain swap aggregator focused on utility and decentralization. The community is heavily discussing the project's potential as a leading memecoin, often drawing comparisons to early Shiba Inu, and highlighting its consistent trending presence across platforms. Many believe Sailana is building something unique and urge others not to overlook its ongoing development and future innovations planned for 2026.

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Speculation surrounding a potential SpaceX IPO is driving significant buzz across the aerospace sector, with community attention intensely focused on "SpaceX IPO plays." Among these, $MNTS is trending due to its partnership with SpaceX, serving as a critical payload deployment provider for upcoming Falcon 9 missions, including high-profile DoD and commercial satellites. Its notably low total share count and recent contract awards are fueling comparisons to past explosive "meme stock" movements, making it a prominent talking point among investors seeking indirect exposure to the surging space market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anavex Life Sciences' (AVXL) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Anavex Life Sciences in a research report on Friday...

Anavex Life Sciences (AVXL) Projected to Post Quarterly Earnings on Monday

Anavex Life Sciences (NASDAQ:AVXL) will be releasing its Q4 2025 earnings before the market opens on Monday, December 22. (View Earnings Report at...

<ul class="summary-bullets"><li>The company now intends to request a re-examination of the opinion which would be undertaken by a different set of reviewers that conduct a new examination.</li><li>Anavex submitted an application to the EMA for Blarcamesine in November 2024.</li></ul>Shares of Anavex Life Sciences Corp. (AVXL) fell 3% after hours on Friday after the company said that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a negative opinion on its application seeking approval for the drug Blarcamesine in treating Alzheimer’s disease.In November, Anavex <a href="https://stocktwits.com/news-articles/markets/equity/avxl-shares-slump-pre-market-after-ema-committee-fails-to-recommend-approval-for-alzheimers-drug/cLPQ7tkRE4E">said </a>it was informed by the CHMP of a negative trend vote on its application for Blarcamesine following its oral explanation in a session held behind closed doors on Nov. 11. The company was awaiting a formal opinion from the committee.<h2 class="st-heading-2">Negative Opinion ‘As Expected’</h2>Anavex <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-provides-update-on-regulatory-review-in-the-eu-for-blarcamesine-to-treat-early">said</a> on Friday that the CHMP has indeed adopted a negative opinion “as expected.” CHMP provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens chances for an EMA approval for the drug.The company now intends to request a re-examination of the opinion which would be undertaken by a different set of reviewers that conduct a new examination, independent from the first opinion.Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December. If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.Besides Alzheimer’s, Anavex is also studying Blarcamesine in treating Parkinson's disease dementia and Rett syndrome.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AVXL stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.A Stocktwits user opined that this is the best time for big pharma players “to throw bone for this company” provided the low share price and “promising assets.”&nbsp;<stembedurl>https://stocktwits.com/lookupdownside/message/639061239</stembedurl><a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is down 63% this year and by 52% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/oracle-denies-data-center-delay-report-after-shares-slide-on-openai-build-out-concerns/cLICt16RE8O">Oracle Denies Data Center Delay Report After Shares Slide On OpenAI Build-Out Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Anavex Stock Slides After Hours On EMA Panel’s Negative Alzheimer’s Drug Opinion — Retail Traders Talk Buyout Potential

Anavex said on Friday that the CHMP has indeed adopted a negative opinion “as expected.”

Equity

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (Anavex or the Company) (NASDAQ...

Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL)

Anavex Life Sciences (AVXL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Anavex Life Sciences' (AVXL) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued a "buy" rating and set a $24.00 price target on shares of Anavex Life Sciences in a research report on Wednesday...

Anavex Life Sciences (NASDAQ:AVXL) Posts Earnings Results, Beats Expectations By $0.02 EPS

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating...

<ul class="summary-bullets"><li>The company said its net loss for the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024.</li><li>The company is now seeking a re-examination of CHMP’s opinion on its Alzheimer’s drug, Blarcamesine.&nbsp;</li><li>It expects a cash runway of more than 3 years.</li></ul> Shares of Anavex Life Sciences Corp. (AVXL) jumped 10% on Monday afternoon after the company reported a lower-than-expected loss for the fourth quarter.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provides-business-upd">said</a> that net loss in the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024, and lower than the loss of $0.15 per share expected by analysts, according to data from Fiscal AI.The company ended the quarter with cash and cash equivalents of $102.6 million. It now expects a cash runway of more than 3 years.<h2 class="st-heading-2">Blarcamesine’s Path Forward</h2>Anavex is focused on developing treatments for neurodegenerative disorders like Alzheimer’s. “There are currently an estimated 7.2 million people living with Alzheimer’s disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally, targeted upstream medicines, particularly in the context of early Alzheimer’s disease,” said CEO Christopher U. Missling.Earlier this month, Anavex<a href="https://stocktwits.com/news-articles/markets/equity/avxl-shares-slump-pre-market-after-ema-committee-fails-to-recommend-approval-for-alzheimers-drug/cLPQ7tkRE4E"> said</a> that a European Medicines Agency (EMA) committee did not recommend approval of the company’s application for its Alzheimer’s drug, Blarcamesine. The Committee for Medicinal Products for Human Use provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens the chances of EMA approval for the drug.The committee is expected to adopt a formal opinion on the application at its December meeting, the company said, while adding that it intends to request a re-examination of the committee’s opinion. The firm reiterated the course of action on Tuesday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AVXL stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user opined that they are “cautiously optimistic” about the stock’s future.<stembedurl>https://stocktwits.com/Filldagap/message/637414773</stembedurl>AVXL stock is down 68% this year and by 63% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pmcb-stock-jumps-after-company-sells-stake-in-femasys/cL52o2lREgL">PMCB Stock Jumps 25% After Company Sells Stake In Femasys</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug

Anavex ended the quarter with cash and cash equivalents of $102.6 million.

A Preview Of Anavex Life Sciences's Earnings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Current Price	$3.72
Prev Close	$3.73
Open	$3.71
Dividend Yield	0.00%
50-Day Moving Average	$5.68
Beta	1.49
Avg. Volume	4.27M
PE Ratio	-6.84

52-Week High	$14.44
52-Week Low	$2.86
Market Capitalization	$332.37M
EPS (Annual)	-$0.5438
Price to Book	3.40
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

AVXL
Anavex Life Sciences Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AVXL News

AVXLAnavex Life Sciences Corp